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Background/Aims
The prevalence of gastroesophageal reflux disease (GERD) is high in patients with idiopathic pulmonary fibrosis (IPF). GERD may cause 
chronic microaspiration that leads to repeated subclinical lung injury, which leads to pulmonary fibrosis. Although some studies have 
suggested that proton pump inhibitors (PPI) were associated with a good prognosis in IPF, their effects remain unclear.
Methods
We retrospectively reviewed 786 consecutive adult patients with IPF at Seoul National University Bundang Hospital between April 
2003 and March 2015. 
Results
Mean duration of follow-up was 2.6 ± 2.8 years. Of the 786 patients with IPF, 107 (13.6%) were given diagnoses of GERD, and 103 
(13.1%) died due to IPF-related pneumonia or respiratory failure. The prevalence of GERD and the cumulative incidence of de novo 
GERD increased depending on the period of follow-up in patients with IPF. Patients administered PPI for more than four months had 
a lower IPF-related mortality rate than patients on PPI less than 4 months (Log-rank P-value = 0.024 in Kaplan-Meier curve). In a 
univariate and multivariate Cox regression hazard model, younger age (hazard ratio [HR], 1.06; 95% CI, 1.03-1.10; P = 0.001), higher 
initial forced vital capacity (HR, 0.98; 95% CI, 0.96-0.99; P = 0.004), and longer duration of PPI use (HR, 0.97; 95% CI, 0.95-1.00; P 
= 0.022), but not a diagnosis of GERD, were significantly associated with lower IPF-related mortality.
Conclusions
In Korean patients with IPF, the prevalence of GERD was lower than in other countries. PPI use for at least 4 months may have a 
protective effect against IPF-related mortality.
(J Neurogastroenterol Motil 2016;22:444-451)
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Introduction  
Previous studies have reported the relationship between gastro-
esophageal reflux disease (GERD) and respiratory disease, includ-
ing asthma, chronic obstructive pulmonary disease (COPD), and 
idiopathic pulmonary fibrosis (IPF).1-3 In particular, many studies 
have reported the higher prevalence of GERD in IPF.4-13 The 
prevalence of GERD in patients with IPF was reportedly 67 to 
88% in Western populations,8-10,12,13 and 62.3% (43 of 69 patients) 
in China.6 Although the mechanism is unclear, chronic microaspira-
tion due to GERD has been considered to be one of the causes of 
IPF through repeated subclinical injury to the lungs.7,8,12,14-17 This 
is supported by the lower pH or elevated concentrations of pepsin 
in bronchoalveolar lavage in patients with IPF.18,19 Esophageal ma-
nometry in patients with GERD and IPF shows decreased lower 
esophageal sphincter pressure (LESP) with normal esophageal 
function, and further decreased upper esophageal sphincter pres-
sure than LESP.6,20 These findings may explain why typical symp-
toms such as heartburn are uncommon in patients with IPF.6,14,16,20
Moreover, Lee et al21 reported that GERD influences the sur-
vival rate in patients with IPF, as well as the development of IPF. 
This study also reported that symptoms of GERD, a history of 
GERD, medication for GERD, and Nissen fundoplication were 
independent predictors of longer survival for IPF. Another study 
reported that antacid therapy including antihistamines, sucralfate, 
and proton pump inhibitors (PPI) reduced the frequency of acute 
exacerbations and slowed the deterioration of forced vital capacity 
(FVC).22 Another case series showed that anti-reflux therapy with 
PPI alone stabilized or improved pulmonary function tests in IPF.23 
Standard treatment for atypical GERD has been proposed as 
PPI twice daily for 3-4 months.3,24 In cases of laryngopharyngeal 
reflux, some experts recommend treatment with PPI for at least 
4-6 months in order to improve the symptoms.25,26 However, in 
respiratory manifestations of GERD, the appropriate duration and 
effectiveness of PPI medication are still controversial.
The aims of this study were to investigate the prevalence of 
GERD in Korean patients with IPF, and to compare the differences 
in survival according to the duration of PPI treatment. 
Materials and Methods  
Study Populations
This is a retrospective, single-center cohort study involving 
a total of 917 consecutive adult patients with IPF seen at Seoul 
National University Bundang Hospital between April 2003 and 
March 2015. Of these, patients with underlying asthma or COPD 
were excluded; therefore, a total of 786 patients were enrolled. All 
patients were given diagnoses of IPF by respiratory specialists. 
IPF is defined as a specific form of chronic, progressive, fibrosing 
interstitial pneumonia of unknown cause, occurring primarily and 
in association with histologic and/or radiologic patterns of usual in-
terstitial pneumonia.27 Demographic data including age, sex, body 
mass index (BMI), concomitant diseases, alcohol consumption, 
smoking, medication history, pulmonary function, and computed 
tomography data were retrospectively collected from a review of 
medical records. GERD was diagnosed according to typical symp-
toms including typical heartburn and acid regurgitation. Erosive 
reflux disease (ERD) was defined by mucosal breaks on endoscopy, 
and nonerosive reflux disease (NERD) was diagnosed after reflux 
monitoring and/or PPI response in addition to negative endos-
copy. This study was conducted in accordance with the amended 
Declaration of Helsinki. The Institutional Review Board of Seoul 
National University Bundang Hospital reviewed and approved the 
protocol (B-1507-306-126). 
Outcome
The primary outcomes were the prevalence of GERD and cu-
mulative incidence of de novo GERD in patients with IPF at Seoul 
National University Bundang Hospital in Korea. The secondary 
outcomes were IPF-related mortality and the predictive risk factors 
for IPF-related mortality according to variables, including duration 
of medication with PPI in patients with IPF.
Statistical Methods
For between-group comparisons, the Chi-square test or 
Fisher’s exact test (for situations with small frequencies) was used 
for categorical variables, and Student’s t test was used for continu-
ous variables. The cumulative incidence of de novo GERD and 
IPF-related mortality curves were constructed using Kaplan-Meier 
analysis, and compared using the log-rank test. The association be-
tween variables and IPF-related mortality was assessed by univari-
ate and multivariate Cox proportional hazard regression analysis. 
The risk was expressed by calculating the hazard ratio (HR) and 
95% confidence interval (CI). A P-value < 0.05 was considered to 
indicate a statistically significant difference. All statistical analyses 
were performed using SPSS 22.0 (SPSS, Chicago, IL, USA).
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Results  
Baseline Characteristics 
Mean age ± standard deviation was 75.2 ± 10.3 years, and 
559 (71.1%) were men (Table 1). Mean BMI was 22.6 ± 3.9 
kg/m2. Mean duration of follow-up was 2.6 ± 2.8 years. A total 
294 (37.4%) were given prednisolone. Of the 128 who were given 
azathioprine, 118 (92.2%) were coadministered prednisolone; aza-
thioprine alone was given to 10 patients. Inhaled corticosteroids/
long-acting beta2-agonists (ICS/LABA) were used in 42 (5.3%). 
We performed esophagogastroduodenoscopy (EGD) in 25.2% of 
cases, while esophageal manometry and 24-hour pH monitoring 
were done in only 2 patients.
There was no significant difference in mean age, BMI, and 
sex between patients with and without GERD. However, the pro-
portion undergoing EGD was significantly higher for those with 
GERD than in those without GERD (78.5% vs 16.8%, P < 0.001) 
(Table 1). Initial FVC was significantly higher and duration of 
follow-up was also significantly longer in patients with GERD. In 
addition, hypertension (HTN), diabetes mellitus, and angina were 
more likely in patients with GERD.
The Prevalence of Gastroesophageal Reflux 
Disease and the Cumulative Incidence of De Novo 
Gastroesophageal Reflux Disease in Idiopathic 
Pulmonary Fibrosis
Of the 786 patients with IPF, GERD was diagnosed in 107 
(13.6%). Of these 107, 84 (78.5%) underwent EGD for diagno-
sis of GERD, and 23 (21.5%) with typical symptoms were given 
diagnoses without EGD (Table 1). Of 84 patients who underwent 









Age (yr) 75.2 ± 10.3 75.2 ± 9.9 75.1 ± 10.3 0.945
Sex (male) 559 (71.1) 78 (72.9) 481 (70.8) 0.662
BMI (kg/m2) 22.6 ± 3.9 22.5 ± 3.8 22.6 ± 4.0 0.849
Duration of follow-up (yr) 2.6 ± 2.8 3.9 ± 2.9 2.3 ± 2.8 < 0.001a
Initial FVC (% predicted) 84.0 ± 20.5 89.3 ± 19.8 83.0 ± 20.5 0.006a
Duration of PPI (wk) 24.5 ± 54.5 47.9 ± 88.9 15.1 ± 26.8 0.001a
Alcohol consumption 195 (37.2) 29 (36.3) 166 (37.4) 0.846
Smoking history 269 (65.9) 43 (62.3) 226 (66.7) 0.487
Medication history
    Acetylcysteine 385 (49.0) 67 (62.6) 318 (46.8) 0.002a
    Prednisolone 294 (37.4) 40 (37.4) 254 (37.4) 0.996
    Azathioprine 128 (16.3) 16 (15.0) 112 (16.5) 0.688
    Tiotropium 46 (5.9) 8 (7.5) 38 (5.6) 0.441
    ICS/LABA 42 (5.3) 5 (4.7) 37 (5.4) 0.740
    Warfarin 26 (3.3) 4 (3.7) 22 (3.2) 0.771
    Sildenafil 19 (2.4) 7 (6.5) 12 (1.8) 0.009a
EGD 198 (25.2) 84 (78.5) 114 (16.8) < 0.001a
    Peptic ulcer disease 55/198 (27.8) 26/84 (31.0) 29/114 (25.4) 0.392
Comorbidity
    HTN 143 (18.2) 32 (29.9) 111 (16.3) 0.001a
    DM 125 (15.9) 22 (20.6) 103 (15.2) 0.156
    Angina 74 (9.4) 18 (16.8) 56 (8.2) 0.005a
    CKD 11 (1.4) 0 (0.0) 11 (1.6) 0.377
    LC 6 (0.8) 0 (0.0) 6 (0.9) 1.000
    Pulmonary HTN 6 (0.8) 1 (0.9) 5 (0.7) 0.586
aP-value was below 0.05.
GERD, gastroesophageal reflux disease; BMI, body mass index; FVC, forced vital capacity; PPI, proton pump inhibitor; ICS/LABA, inhaled corticosteroids/long-
acting beta2-agonists; EGD, esophagogastroduodenoscopy; HTN, hypertension; DM, diabetes mellitus; CKD, chronic kidney disease; LC, liver cirrhosis.
Data are presented as mean ± SD or number (%).
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EGD, the proportion with ERD was 18 (21.4%), and 66 (78.6%) 
had NERD (Fig. 1A). Of 679 IPF patients without GERD, 161 
(23.7%) used PPI for treatment of peptic ulcer or diagnosis of 
GERD.
On the other hand, 57/107 (53.3%) were newly diagnosed with 
GERD following the diagnosis of IPF (de novo GERD) (Fig. 
1B). However, the other cases of GERD (50/107, 46.7%) were 
diagnosed before IPF was diagnosed.
The prevalence of GERD tended to increase as the follow-
up period increased (Fig. 2A). In 736 patients without underlying 
GERD, the cumulative incidence of de novo GERD increased 
consistently after the diagnosis of IPF (Fig. 2B).
Predictive Risk Factors for Idiopathic Pulmonary 
Fibrosis-related Mortality
Of 786 patients with IPF, 156 (19.8%) died regardless of the 
cause, and 103 (13.1%) died due to IPF-related pneumonia or 
respiratory failure. In Kaplan-Meier analysis, IPF-related mortality 
was significantly lower in those who took PPI for more than four 
months than in those who took PPI for less than four months (log 
rank, P = 0.024). However, when the cut-off value was set at 2 or 
3 months, there was no significant difference in IPF-related mortal-
ity (Fig. 3).







(50, 46.7%) De novo GERD
(57, 53.3%)
Figure 1. The distribution of gastro-
esophageal reflux disease (GERD) 
according to classification. (A) The pro-
portion of erosive reflux disease (ERD) 
and non-erosive reflux disease (NERD) 
in GERD patients with esophagogas-
troduodenoscopy (EGD) (n = 84). (B) 
The proportion of de novo GERD in 
patients with GERD (n = 107).
Figure 2. The prevalence and incidence of gastroesophageal reflux disease (GERD) in idiopathic pulmonary fibrosis (IPF). (A) Kaplan-Meier 
curves of the prevalence of GERD according to duration of follow-up in patients with IPF. (B) Kaplan-Meier curves of the cumulative incidence 
of de novo GERD after diagnosis of IPF. 
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mortality was significantly associated with age, BMI, initial FVC, 
prednisolone, azathioprine, ICS/LABA, PPI for four months, du-
ration of PPI use, underlying HTN, and pulmonary HTN (Table 
2). In the multivariate Cox model 1, IPF-related mortality was 
significantly associated with age, initial FVC, azathioprine, pulmo-
nary HTN, and duration of PPI use. However, in the multivariate 
Cox model 2, IPF-related mortality was associated with only age, 
initial FVC, and HTN, but not GERD or PPI dosing. In both 
multivariate Cox models, the hazard risk for IPF-related mortality 
increased with increasing age and decreasing initial FVC. However, 
there was no significant association between IPF-related mortality 
and GERD in either model. Although there was an inverse associa-
tion between IPF-related mortality and duration of PPI dosing in 
model 1, PPI taken for 4 months was not a significant independent 
predictive factor for IPF-related mortality in model 2. 
Discussion  
In the present study, the prevalence of GERD was 13.6% 
(107/786) in patients with IPF in Korea. This result is much 
lower than the prevalence reported in other countries, including 
China.6,8-10,12,13 In addition, this result is lower than the prevalence 
of asthma or COPD previously reported in the Korean popula-
tion (55.6% and 30%, respectively).28,29 While this low prevalence 
of GERD in IPF is probably due to ethnic characteristics in the 
Korean population, there is a possibility that GERD was diagnosed 
by gastroenterologists based on strict criteria. Furthermore, this may 
explain why typical GERD symptoms such as heartburn or reflux 
Duration of follow-up (yr)
A
Duration of follow-up (yr)
B















































Less than 2 months
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Log-rank -value: 0.571P
Duration of follow-up (yr)
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Less than 3 months
Over 3 months
Log-rank -value: 0.144P
Figure 3. Kaplan-Meier estimates of idiopathic pulmonary fibrosis 
(IPF)-related mortality according to proton pump inhibitor (PPI) 
use. Green continuous line represents patients with PPI use over the 
cut-off value. Blue dotted line represents patients with PPI use for 
less than the cut-off value. (A) The cut-off value was 2 months, (B) 3 
months, and (C) 4 months. 
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were uncommon in patients with respiratory manifestations of 
GERD.6,14,16,20 Another possibility is that the prevalence of GERD 
may have been underestimated in the present study, because 31.8% 
(248/786) were lost to follow-up within six months. Among patients 
who continued follow-up for over six months, the prevalence of 
GERD in IPF was slightly increased to 17.3% (93/538). Further-
more, a longer duration of follow-up tended to increase the preva-
lence of GERD (up to 65.3% on the Kaplan-Meier curve) (Fig. 
1A). 
We investigated the time to onset of GERD, and found that of 
107 patients with GERD and IPF, 50 (46.7%) had been diagnosed 
with GERD before a diagnosis of IPF, and 57 (53.3%) were newly 
diagnosed after a diagnosis of IPF. This suggests that GERD 
could occur at any time, regardless of the diagnosis of IPF. In 736 
patients without underlying GERD at the time of diagnosis of IPF, 
the cumulative incidence of de novo GERD showed a tendency to 
continuous increase (Fig. 2B). However, there was no predictive 
factor for the development of de novo GERD in patients with IPF.
IPF-related causes of death, including pneumonia or respira-
tory failure, totaled 13.1% (103/786), and death due to any cause 
totaled 19.8% (156/786). In the present study, older age and lower 
initial FVC increased IPF-related mortality significantly in mul-
tivariate Cox regression analysis (Table 2). Although a history of 
azathioprine use was also associated with more frequent IPF-related 
deaths, this association may be due to confounding factors based 
on the severity of IPF. In a retrospective cohort study in the USA, 
Lee et al21 reported that the presence of reflux symptoms, GERD, 
GERD medication, and Nissen fundoplication were significantly 







HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value
Age (yr) 1.03 (1.01-1.05) 0.005b 1.06 (1.03-1.10) 0.001b 1.05 (1.02-1.09) < 0.001b
BMI (kg/m2) 0.92 (0.88-0.97) 0.003b 1.01 (0.92-1.11) 0.872 0.99 (0.92-1.06) 0.729
Sex (male) 0.78 (0.49-1.22) 0.270
Alcohol consumption 1.24 (0.83-1.85) 0.305
Smoking history 0.84 (0.65-1.70) 0.842
Initial FVC (% predicted) 0.98 (0.97-0.98) < 0.001b 0.98 (0.96-0.99) 0.004b 0.98 (0.97-0.99) < 0.001b
Prednisolone 2.09 (1.41-3.11) < 0.001b 1.01 (0.48-2.42) 0.852 1.23 (0.63-2.40) 0.544
Azathioprine 3.01 (2.03-4.46) < 0.001b 2.79 (1.31-5.94) 0.008b 1.85 (0.99-3.46) 0.056
ICS/LABA 2.13 (1.13-3.99) 0.019b 1.00 (0.38-2.67) 0.997 1.32 (0.58-3.02) 0.507
Tiotropium 1.13 (0.55-2.32) 0.746
Acetylcysteine 0.87 (0.59-1.29) 0.495
Sildenafil 0.90 (0.29-2.83) 0.857
Warfarin 0.44 (0.11-1.77) 0.246
PPI for 2 monthsa 0.87 (0.54-1.41) 0.572
PPI for 4 monthsa 0.47 (0.23-0.92) 0.028b 0.51 (0.21-1.22) 0.130
Duration of PPI (wk) 0.97 (0.96-0.99) 0.001b 0.97 (0.95-1.00) 0.022b
GERD 0.40 (0.20-0.80) 0.009b 0.62 (0.26-1.46) 0.274 0.72 (0.33-1.58) 0.413
NERD 0.35 (0.14-0.85) 0.021b
ERD 0.05 (0.00-6.73) 0.228
Peptic ulcer 1.09 (0.43-2.73) 0.857
Pulmonary HTN 4.30 (1.06-17.51) 0.042b 37.89 (4.10-349.89) 0.001b 5.45 (0.71-41.97) 0.104
HTN 0.52 (0.30-0.90) 0.020b 0.55 (0.25-1.20) 0.134 0.50 (0.26 -0.99)  0.046b
DM 1.11 (0.69-1.78) 0.663
Angina 0.60 (0.28-1.30) 0.194
CKD 0.05 (0.00-17.88) 0.313
aCategorical variables were used in the analysis.
bP-value was below 0.05.
HR, hazard ratio; BMI, body mass index; FVC, forced vital capacity; ICS/LABA, inhaled corticosteroids/long-acting beta2-agonists; PPI, proton pump inhibi-
tor; GERD, gastroesophageal reflux disease; NERD, non-erosive reflux disease; ERD, erosive reflux disease; HTN, hypertension; DM, diabetes mellitus; CKD, 
chronic kidney disease.
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associated with longer survival time. Similar to these results, 
GERD was also significantly associated with lower IPF-related 
death in univariate Cox analysis in the present study. However, in 
multivariate Cox regression analysis, GERD itself was not an inde-
pendent predictive factor for IPF-related mortality (Table 2). On 
the contrary, PPI use was correlated with IPF mortality in the pres-
ent study. 
Compared to previous studies, PPI use for longer periods was 
associated with a reduced IPF-related mortality rate. Although PPI 
use for two or three months was not significantly correlated, PPI 
use for over four months showed a lower IPF-related mortality 
rate than use for less than four months (Fig. 2). In addition, longer 
duration of PPI use was a significant independent predictive factor 
for low IPF-related mortality rates in univariate and multivariate 
Cox regression analysis (Table 2). These results suggest that PPI 
use is associated with good prognosis in IPF, and that use of PPI 
for at least four months may have a protective effect against IPF-
related death. However, longer PPI use had a higher correlation 
with IPF-related mortality than did GERD. Because patients with 
GERD had a higher proportion of PPI use than patients without 
GERD (P < 0.001), the association between GERD and survival 
in univariate analysis was probably due to an association between 
GERD and PPI use. Patients with GERD had another basis for 
good prognosis. We surmised that IPF-related mortality may be 
influenced by better FVC at baseline in patients with GERD than 
in those without GERD (Table 1).
The main limitation of the present study was that it was a sin-
gle-center retrospective study. In addition, the lower prevalence and 
mortality rates compared to those in previous studies may have been 
due to the higher proportion of loss to follow-up within 6 months. 
Insufficient evaluation of patients without GERD symptoms may 
also have contributed to underestimation. Furthermore, it should be 
noted that it was difficult to analyze atypical symptoms of GERD 
due to uncertainty of relationship between GERD and these symp-
toms. Therefore, further prospective studies are needed to verify the 
effectiveness of PPI in improving the prognosis of IPF. Another 
limitation is that PPI is also related with community-acquired 
pneumonia (CAP), and CAP is associated with IPF-related mor-
tality. Although CAP might be a confounding factor, this is a rare 
data that improve a statistically significant relationship between PPI 
and IPF-related mortality. Moreover, there are no data available 
regarding patients with IPF and GERD in Korea. 
In conclusion, in Korean patients with IPF, the prevalence of 
GERD was relatively low, compared to other countries. PPI treat-
ment was more important to survival than GERD itself in patients 
with IPF. The IPF-related mortality rate was significantly associ-
ated with the use of PPI medication for longer than four months in 
patients with IPF. 
Acknowledgements: The authors are indebted to J. Patrick 
Barron, Professor Emeritus, Tokyo Medical University and Ad-
junct Professor, Seoul National University Bundang Hospital for 
his pro bono editing of this manuscript.
Financial support: None.
Conflicts of interest: None.
Author contributions: Chang Min Lee and Dong Ho Lee 
had full access to all of the data in the study and take responsibility 
for the integrity of the data and the accuracy of the data analysis; 
Dong Ho Lee had final responsibility for the decision to submit the 
manuscript for publication; Hyuk Yoon, Cheol Min Shin, Young 
Soo Park, and Nayoung Kim contributed to the study concept and 
study design, data acquisition, and data analysis; Byung Kyu Ahn 
and Jae Jin Hwang contributed to the data acquisition and data 
analysis; and Cheol Min Shin and Dong Ho Lee contributed to 
the study design, data acquisition, data analysis and interpretation, 
and writing of the manuscript.
References  
1. el-Serag HB, Sonnenberg A. Comorbid occurrence of laryngeal or 
pulmonary disease with esophagitis in United States military veterans. 
Gastroenterology 1997;113:755-760.
2. Galmiche JP, Zerbib F, Bruley des Varannes S. Review article: respiratory 
manifestations of gastro-oesophageal reflux disease. Aliment Pharmacol 
Ther 2008;27:449-464.
3. Richter JE. Review article: extraoesophageal manifestations of gastro-
oesophageal reflux disease. Aliment Pharmacol Ther 2005;22(suppl 
1):70-80.
4. Bandeira CD, Rubin AS, Cardoso PF, Moreira Jda S, Machado Mda M. 
Prevalence of gastroesophageal reflux disease in patients with idiopathic 
pulmonary fibrosis. J Bras Pneumol 2009;35:1182-1189.
5. Basseri B, Conklin JL, Pimentel M, et al. Esophageal motor dysfunction 
and gastroesophageal reflux are prevalent in lung transplant candidates. 
Ann Thorac Surg 2010;90:1630-1636.
6. Gao F, Hobson AR, Shang ZM, et al. The prevalence of gastro-esoph-
ageal reflux disease and esophageal dysmotility in Chinese patients with 
idiopathic pulmonary fibrosis. BMC Gastroenterol 2015;15:26.
7. Mays EE, Dubois JJ, Hamilton GB. Pulmonary fibrosis associated with 
tracheobronchial aspiration. A study of the frequency of hiatal hernia and 
gastroesophageal reflux in interstitial pulmonary fibrosis of obscure etiol-
451
PPI Effect for Survival in GERD and IPF
Vol. 22, No. 3   July, 2016 (444-451)
ogy. Chest 1976;69:512-515.
8. Patti MG, Tedesco P, Golden J, et al. Idiopathic pulmonary fibrosis: how 
often is it really idiopathic? J Gastrointest Surg 2005;9:1053-1056; dis-
cussion 1056-1058.
9. Raghu G, Freudenberger TD, Yang S, et al. High prevalence of abnor-
mal acid gastro-oesophageal reflux in idiopathic pulmonary fibrosis. Eur 
Respir J 2006;27:136-142.
10. Salvioli B, Belmonte G, Stanghellini V, et al. Gastro-oesophageal reflux 
and interstitial lung disease. Dig Liver Dis 2006;38:879-884.
11. Soares RV, Forsythe A, Hogarth K, Sweiss NJ, Noth I, Patti MG. 
Interstitial lung disease and gastroesophageal reflux disease: key role of 
esophageal function tests in the diagnosis and treatment. Arq Gastroen-
terol 2011;48:91-97.
12. Sweet MP, Patti MG, Leard LE, et al. Gastroesophageal reflux in pa-
tients with idiopathic pulmonary fibrosis referred for lung transplantation. 
J Thorac Cardiovasc Surg 2007;133:1078-1084.
13. Tobin RW, Pope CE 2nd, Pellegrini CA, Emond MJ, Sillery J, Raghu G. 
Increased prevalence of gastroesophageal reflux in patients with idiopathic 
pulmonary fibrosis. Am J Respir Crit Care Med 1998;158:1804-1808.
14. Lee JS. The role of gastroesophageal reflux and microaspiration in idio-
pathic pulmonary fibrosis. Clin Pulm Med 2014;21:81-85.
15. Lee JS, Collard HR, Raghu G, et al. Does chronic microaspiration cause 
idiopathic pulmonary fibrosis? Am J Med 2010;123:304-311.
16. Raghu G, Meyer KC. Silent gastro-oesophageal reflux and microaspira-
tion in IPF: mounting evidence for anti-reflux therapy? Eur Respir J 
2012;39:242-245.
17. Verma S, Slutsky AS. Idiopathic pulmonary fibrosis--new insights. N 
Engl J Med 2007;356:1370-1372.
18. Davis CS, Mendez BM, Flint DV, et al. Pepsin concentrations are 
elevated in the bronchoalveolar lavage fluid of patients with idiopathic 
pulmonary fibrosis after lung transplantation. J Surg Res 2013;185:e101-
e108.
19. Lozo Vukovac E, Lozo M, Mise K, et al. Bronchoalveolar pH and in-
flammatory biomarkers in newly diagnosed IPF and GERD patients: a 
case-control study. Med Sci Monit 2014;20:255-261.
20. Allaix ME, Fisichella PM, Noth I, Herbella FA, Borraez Segura B, 
Patti MG. Idiopathic pulmonary fibrosis and gastroesophageal reflux. 
Implications for treatment. J Gastrointest Surg 2014;18:100-104; discus-
sion 104-105.
21. Lee JS, Ryu JH, Elicker BM, et al. Gastroesophageal reflux therapy 
is associated with longer survival in patients with idiopathic pulmonary 
fibrosis. Am J Respir Crit Care Med 2011;184:1390-1394.
22. Lee JS, Collard HR, Anstrom KJ, et al. Anti-acid treatment and disease 
progression in idiopathic pulmonary fibrosis: an analysis of data from 
three randomised controlled trials. Lancet Respir Med 2013;1:369-376.
23. Raghu G, Yang ST, Spada C, Hayes J, Pellegrini CA. Sole treatment 
of acid gastroesophageal reflux in idiopathic pulmonary fibrosis: a case 
series. Chest 2006;129:794-800.
24. Heidelbaugh JJ, Gill AS, Van Harrison R, Nostrant TT. Atypical 
presentations of gastroesophageal reflux disease. Am Fam Physician 
2008;78:483-488.
25. Belafsky PC, Postma GN, Koufman JA. Laryngopharyngeal reflux 
symptoms improve before changes in physical findings. Laryngoscope 
2001;111:979-981.
26. Vaezi MF, Hicks DM, Abelson TI, Richter JE. Laryngeal signs and 
symptoms and gastroesophageal reflux disease (GERD): a critical assess-
ment of cause and effect association. Clin Gastroenterol Hepatol 2003;1: 
333-344.
27. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT 
statement: idiopathic pulmonary fibrosis: evidence-based guidelines for 
diagnosis and management. Am J Respir Crit Care Med 2011;183:788-
824.
28. Kim SW, Lee JH, Sim YS, Ryu YJ, Chang JH. Prevalence and risk fac-
tors for reflux esophagitis in patients with chronic obstructive pulmonary 
disease. Korean J Intern Med 2014;29:466-473.
29. Lee YB, Lim JH, Choi YJ, et al. [Effects of proton pump inhibitors in 
asthmatics with gastroesophageal reflux disease.] Korean J Gastroenterol 
2011;58:178-183. [Korean]
